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Abstract
Background: Heroin addiction often severely disrupts normal social functioning. The aims of this multi-centre study of
heroin users in long-term replacement treatment were: i) to provide information on aspects of social condition such as
employment, educational background, living status, partner status and any history of drug addiction for partners,
comparing these data with that of the general population; ii) to assess the prevalence of hepatitis, syphilis and HIV,
because serological status could be a reflection of the social conditions of patients undergoing replacement treatment
for drug addiction; iii) to analyse possible relationships between social conditions and serological status.
Methods: A cross-sectional study was carried out in sixteen National Health Service Drug Addiction Units in northern
Italy. The data were collected from February 1, 2002 to August 31, 2002. Recruitment eligibility was: maintenance
treatment with methadone or buprenorphine, treatment for the previous six months, and at least 18 years of age. In the
centres involved in the study no specific criteria or regulations were established concerning the duration of replacement
therapy. Participants underwent a face-to-face interview.
Results: The conditions of 1091 drug treatment patients were evaluated. The mean duration of drug use was 14.5 years.
Duration was shorter in females, in subjects with a higher educational background, and in stable relationships. Most (68%)
had completed middle school (11–14 years of age). Seventy-nine percent were employed and 16% were unemployed.
Fifty percent lived with their parents, 34% with a partner and 14% alone. Males lived more frequently with their parents
(55%), and females more frequently with a partner (60%). Sixty-seven percent of male patients with a stable relationship
had a partner who had never used heroin. HCV prevalence was 72%, HBV antibodies were detected in 42% of patients,
while 30% had been vaccinated; 12.5% of subjects were HIV positive and 1.5% were positive for TPHA.
Conclusion: A significant percentage of heroin users in treatment for opiate addiction in the cohort study have
characteristics which indicate reasonable integration within broader society. We posit that the combination of effective
treatment and a setting of economic prosperity may enhance the social integration of patients with a history of heroin
use.
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There is a tendency, not confined to popular opinion, to
regard illicit drug users (DUs) as hopelessly enmeshed in
their addiction and utterly without prospects for better-
ment [1]. Heroin addiction often severely disrupts normal
social functioning and often leads to severe social stigma-
tization [2]. The frequent alternation between states of
drug induced euphoria and withdrawal, and the time,
effort and money needed to obtain the drug makes it quite
difficult to maintain employment and satisfactory social
relationships. The goals of addiction treatment therefore
usually include not only reducing/eliminating illicit drug
use but also re-integrating or integrating the addict into
society. While there is substantial literature indicating the
effectiveness of drug abuse treatment in improving the
social functioning of addicts [2-4], there also appears to
be the public perception that drug abuse treatment is
severely limited in integrating former drug addicts into
society at large [3,5].
The aims of this multi-centre study of heroin users in
long-term replacement treatment in northern Italy were: i)
to provide information on aspects of social integration
such as employment, educational background, living sta-
tus (living with whom), partner status and any history of
drug addiction of partners; ii) to assess the prevalence of
hepatitis B virus (HBV), hepatitis C virus (HCV), human
immunodeficiency virus (HIV) and syphilis, because sero-
logical status needs to be considered in relation to the
potential social integration of drug treatment patients; iii)
to analyse possible relationships between social condi-
tions and serological status. Numerous studies have been
carried out in order to analyse the effectiveness of long-
term maintenance treatment for heroin users [6-8]. The
approach of this study was to collect available data on
patients actively undergoing replacement treatment. The
aim was to assess the social conditions of a large cohort of
patients undergoing drug replacement treatment, com-
pared to the general population in northern Italy. Data are
presented for patients in maintenance treatment for at
least six months. The study was carried out in the Veneto
Region, in the north of Italy, where the unemployment
rate in 2001 was 4% and 9.5% of the population are grad-
uates. In 1999, the per capita gross domestic product
(GDP) in this area was € 20,286, higher than the average
for Italy as a whole € 17,086 [9].
Methods
Population
The data presented in this cross-sectional study were col-
lected from February 1, 2002 to August 31, 2002, in 16
National Health Service Drug Addiction Units (NHS-
DAUs). All NHS-DAUs contributing data were part of a
Regional Scientific Research Group (GICS in the Italian
acronym) dealing with drug problems. These publicly
funded NHS-DAUs provide counselling, treatment for
drug withdrawal, agonist and antagonist therapy, medical
care, and psychological therapy, as described elsewhere
[10]. NHS-DAUs only treat outpatients. Recruitment eligi-
bility was based on three criteria: i) maintenance treat-
ment with methadone or buprenorphine; ii) treatment for
the previous six months; iii) at least 18 years of age. In the
centres involved in the study, the clinical approach of
replacement therapy was to achieve successful ongoing
maintenance rather than abstinence. In these centres no
specific criteria or regulations were established concerning
the duration of replacement therapy. Eligible and con-
senting participants underwent standardised face-to-face
interviews carried out by doctors and nurses in each cen-
tre. Participation in the study was voluntary and anony-
mous. No incentive of any kind was provided for
participation. The majority of those declining to be inter-
viewed stated that they did not have the 20–30 minutes
required to complete the questionnaire. Questions regard-
ing current behaviour (employment, educational back-
ground, living status, partner status, history of drug
addiction of the partner and serological status for infec-
tious diseases) referred to the six-month period prior to
the interview. Written and signed informed consent was
obtained. The study has been approved by the local Ethi-
cal Committee.
The classification of employment and unemployment was
consistent with the criteria of the European Union, which
uses the principles of the International Labour Office and
which the Italian Institute of Statistics (ISTAT) applies to
data concerning the general population [11]. The defini-
tion of an employed person is someone of at least fifteen
years of age with one of the following characteristics: 1)
regular employment even if no work was done during the
reference week; 2) paid work of at least one hour during
the reference week. The classification of an unemployed
person was met by subjects with one of the following
characteristics: 1) they said they were looking for employ-
ment; 2) they had actively sought employment in the 4-
week period prior to the interview; 3) they were willing to
immediately take employment, if offered. The Interna-
tional Standard Classification of Education was used for
the classification of educational status. Vocational status
was considered separately.
Laboratory analyses
Serological testing was performed at 16 different laborato-
ries. The analysis of serological status was part of a sched-
uled entry medical examination. For determination of
anti-Hepatitis C Virus, Cobas Core HCV EIA II (Roche
Laboratories, Mannheim, Germany) was used. Human
immunodeficiency virus antibodies were assessed by
enzyme-linked immunosorbent assay (ELISA; Biotest,
Germany) and confirmed with Western blot (DiaSorin,Page 2 of 11
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Virus markers (anti-HBs, total anti-HBc, HBs-Ag), all lab-
oratories used Cobas Core EIA test kits (Roche Laborato-
ries, Mannheim, Germany); to determine markers for
syphilis, the Treponema pallidum haemoagglutination
test (TPHA) was used. All labs used standard methods
specified by the test kit manufacturers.
Statistical analysis
Chi-squared and Fisher's exact tests were used to assess
relationships between categorical variables. Univariate
and multivariate association of various factors with the
duration of drug use was assessed using the Kruskal-Wallis
test and a linear regression model, respectively. The good-
ness-of-fit of the linear model was assessed through stand-
ard diagnostics. To avoid biased estimates, we chose to
leave age out of the model. The data from the subjects in
drug abuse treatment were compared, wherever possible,
with data for the general population in northern Italy
[9,11,12]. To ensure the consistency of the comparison
with the general population, which has a slightly different
age distribution, the direct standardisation method was
used [13]. To assess the association of social integration
variables with serological variables, the following logistic
regression models were fitted (one for each serological
variable): logit (θ) = α + β1,1..15 (recruitment site) + β2
(age) + β3 (sex) + β4 (duration of drug use) + β5,1..3 (educa-
tion) + β6,1..2 (employment status) + β7,1..3 (living status) +β8,1..2 (partner status) + β9,1.2 (partner's use of heroin) + ε
where: θ was the probability of HIV, HBV, HCV and
TPHA, respectively, and ε was a random error following a
binomial distribution [13]. All the independent variables
but age were included as factors. Due to co-linearity
between "partner's use of heroin" and "partner status", the
two variables were combined: "steady relationship with a
non drug user partner", "steady relationship with a drug
user", "no steady relationship or no partner". The le Ces-
sie-van Houwelingen normal test statistic was used to
assess the goodness-of-fit of the model [14]. Statistical




During the study period, 1759 patients were under treat-
ment in 16 centres (NHS-DAU). Of the total, 530 were not
eligible because they had been in replacement therapy for
less than six months, or were treated with naltrexone or
other forms of therapy for opiate drugs, or were being
treated for addiction to substances other than heroin. Of
the 1229 eligible subjects, 138 (11.2%) did not agree to
take the test and 1091 (88.8%) underwent standardised
interviews. Of the interviewees, 920 (84%) were males
and 171 (16%) were females. The mean age was 33.0
years (SD: 6.4 years), 50% were between 25 and 35 years
old. The most common therapy was methadone (88%);
these patients were, on average, older than patients receiv-
ing buprenorphine (p = .002) See Table 1 for a detailed
view of social characteristics.
Drug use characteristics
A large majority (89%), reported injecting as their princi-
pal route of heroin administration before starting treat-
ment, and 11% reported intranasal use. The youngest
patients (age<35 years old) more frequently sniffed her-
oin than older subjects (13.2% vs 7.9%, p < 0.006). The
mean duration of drug use was 14.5 years (SD = 6.8). A
differential duration of drug use was observed for
buprenorphine DUs vs methadone DUs (medians were
12 and 14, respectively, Kruskal-Wallis test p = 0.0073),
educational levels (median for elementary school DUs
was 16, 14 for middle school DUs, 12 for vocational
school DUs and 12 for secondary or higher school DUs; p
< 0.0001), living status (median was 12, 16, 16, 10 for
DUs living with parents, a partner, alone or friends,
respectively; p < 0.0001). No differences were observed
for gender (p = 0.2150) and employment status (p =
0.0912). The correlation between duration and age was
0.7 8 (95%CI: 0.75–0.80). The selected model included
the recruitment site, gender, therapy, educational level,
employment status, living status and partner status. The
fitting proved reasonable, with normally distributed resid-
uals and limited heteroscedasticity (see Additional file 1).
Results are reported in Table 2. Males used heroin for a
longer time than females (estimated regression coefficient
b = 1.51, 95%CI: 0.42, 2.60). The higher the educational
level the lower the duration of drug use (b = -2.10, 95%CI:
(-3.59, -0.61), b = -3.37, 95%CI: (-5.17, -1.56); b = -4.23,
95%CI: (-6.03, -2.43) for middle, vocational and second-
ary or higher school level, respectively, versus elementary
school). With reference to living status, living with a part-
ner (b = 4.85, 95%CI: 3.57,6.13) and living alone (b =
2.25, 95%CI: 1.08,3.53) are associated with increased
drug use duration. Subjects in stable relationships (mar-
ried or unmarried) had a shorter duration drug use than
subjects without a stable partner (b = -2.75, 95%CI: (-
3.85, -1.65) and b = -2.23, 95%CI: (-3.87, -0.59), respec-
tively) (Table 2).
Educational status
Seven percent of subjects had attended only primary
school, 68% attended until the school-leaving age in Italy,
and 12% had finished secondary school. Females had
higher educational levels than males (p = 0.001, Table 1).
Compared to the 15–49 year old population of northern
Italy, the cohort of patients had a lower educational back-
ground (p < .001): in fact they were concentrated in the
lowest level of education (7% in the elementary school
and 68% in the middle school vs 7% and 41%, respec-
tively, in the general population). Only 12% of patientPage 3 of 11
(page number not for citation purposes)
BMC Public Health 2006, 6:216 http://www.biomedcentral.com/1471-2458/6/216DUs had finished secondary school and almost none had
a degree vs 33% and 9%, respectively, in the general pop-
ulation (see Figure 1).
Employment status
Seventy-nine percent of subjects were employed and 16%
were unemployed. Figure 2 compares unemployment
rates, stratified by age, for the cohort and the general pop-
ulation in northern Italy. The unemployment rate within
the study group was higher than in the general population
(p < 0.01): the difference was 14% for 15–24 age group,
7% for 25–29 age group and 14% for 30–64 age group,
respectively.
Living status
Of the total sample, 50% of patients lived with their par-
ents, 34% with partners and 14% alone. Males lived with
their parents more frequently than females (55% vs 24%),
and females were more frequently living with a partner
(60% vs 29%, p-value for difference in distribution
<0.001, Table 1). When restricted to 18–34 year-old DUs
(to allow comparison with northern Italy population data
[9]), the percentage of DUs living with parents was signif-
icantly smaller than the general population when younger
individuals were considered (18–24), while it was bigger
when older subjects (25–34) were observed (Figure 3, col-
umn 5 and 6). Moreover, when stratifying by gender,
Table 1: Characteristics of the 1091 DUs by gender
Characteristics Females Males Total
No. (%) No. (%) No. (%) p*
Age < 25 21 (12) 84 (9) 105 (10) 0.194
25–35 85 (50) 459 (50) 544 (50)
35–45 62 (36) 332 (36) 394 (36)
>45 3 (2) 45 (5) 48 (4)
Therapy Methadone 154 (90) 806 (88) 960 (88) 0.365
Buprenorphine 17 (10) 114 (12) 131 (12)
Years of drug use < 5 21 (12) 51 (5) 72 (7) 0.016
5–10 27 (16) 174 (19) 201 (18)
10–15 44 (26) 260 (28) 304 (28)
15–20 36 (21) 187 (20) 223 (20)
20–25 35 (20) 170 (19) 205 (19)
≥25 8 (5) 78 (9) 86 (8)
Drug assumption Intravenous 151 (88) 819 (89) 970 (89) 0.784
Sniffing 20 (12) 101 (11) 121 (11)
Education Primary 6 (3) 74 (8) 80 (7) <.001**
Middle 106 (62) 638 (69) 744 (68)
Vocational 22 (13) 109 (12) 131 (12)
Secondary or higher 37 (21) 99 (10) 136 (12)
Employment status Employed 123 (72) 743 (81) 866 (79) <.001**
Continuously† 100 (81) 645 (87) 745 (86)
Discontinuously‡ 23 (19) 98 (13) 121 (14)
Unemployed 31 (18) 141 (15) 172 (16)
Other 17 (10) 36 (4) 53 (5)
Housewives 10 (59) 2 (6) 12 (23)
Students 4 (23) 6 (17) 10 (19)
Invalids-Retired 3 (18) 28 (78) 31 (58)
Living status Parents 41 (24) 504 (55) 545 (50) <.001**
Partner 103 (60) 267 (29) 370 (34)
Alone 24 (14) 133 (14) 157 (14)
Friends 3 (2) 16 (2) 19 (2)
Partner status No steady partner 40 (23) 499 (54) 539 (49) <.001**
A steady partner 131 (77) 421 (46) 552 (51)
Unmarried 99 (76) 296 (70) 395 (72)
Married 32 (24) 125 (30) 157 (28)
Partner's drug use§ No 30 (23) 284 (67) 314 (57) <.001
Yes 101 (77) 136 (33) 237 (43)
Total 171 (16) 920 (84) 1091 (100)
Percentages by column; *chi-squared test p-value for the association between gender and each single variable.
** Fisher's exact test p-value; †Continuously: declaring to be employed; ‡Discontinuously: declaring to work but not continuously;§ Percentages are 
referred to subjects having a steady partner.Page 4 of 11
(page number not for citation purposes)
BMC Public Health 2006, 6:216 http://www.biomedcentral.com/1471-2458/6/216additional differences were observed. The percentage of
females DUs living with parents was lower than the gen-
eral population (p < 0.05) both for the 18–24 and the 25–
34 year-old age groups for women (Figure 3, column 1
and 2). On the other hand, males DUs over 25 years of age
were more often living with parents than males in the gen-
eral population (p < 0.05) (Figure 3, column 4).
Partner status
Fifty-one percent of patients said they had a stable rela-
tionship. Females were more likely to report being in a
stable partnership than males (77% vs 46%, p < 0.001,
Table 1); 14.4% of all patients were married (157/1091),
slightly more females (32/171, or 18.7%) than males
(125/920, or 13.6%) (Table 1). Figure 4 compares the per-
centage of married patients with the general population in
northern Italy: the percentage of married subjects is strik-
ingly lower than the general population at all the ages
except for the 18–24 group (p < 0.001).
History of drug use of the partner
For patients in a stable relationship the history of partners'
drug use was investigated: 43% of patients said they had a
partner with a history of, or current, drug addiction. Her-
oin use by sexual partners varied by gender: 33% of males
had a partner with personal history of drug addiction (cur-
rent or in the past), while 23% of female patients had a
partner who had never used heroin (p < 0.001, Table 1).
Number of children
The female patients reported an average of 0.56 (95%CI:
0.44,0.69) children, significantly lower than the birth rate
in the Veneto Region, which in 1998–2000 was 1.2 chil-
dren per woman between 15 and 49 years of age.
Serological markers
HCV antibodies were detected in 72% of patients; HBV
antibodies were detected in 42%, while 30% had been
vaccinated. HIV prevalence was 12.5% and 1.5% of
patients were positive for TPHA (see Table 3).
Social characteristics and serological status
The goodness-of-fit for logistic models for HIV (z = 1.58,
p = 0.11) and for HCV (z = -0.80, p = 0.42) was satisfying.
In the model for HBV and for the TPHA the adjustment
for recruitment centre was finally omitted because of the
sparseness of data, due to the reduced number of cases.
The statistics for the goodness-of-fit supported the validity
of the models (z = -1.02, p = 0.31 for HBV and z = -1.75
with p = 0.08 for TPHA). The Odds Ratios (ORs) are
Table 2: Results of the regression analysis for the duration of drug use
Characteristics Coeff. † 95%CI ‡ p-value*
Recruitment site (ref.: centre no. 1) centre no. 2 2.14 (-0.92, 5.21) 0.1703
centre no. 3 -2.29 (-4.44, -0.13) 0.0376
centre no. 4 1.35 (-1.05, 3.74) 0.2696
centre no. 5 3.33 (1.36, 5.31) 0.0010
centre no. 6 2.11 (-0.63, 4.86) 0.1315
centre no. 7 1.17 (-1.92, 4.26) 0.4569
centre no. 8 2.60 (-0.12, 5.32) 0.0607
centre no. 9 -0.25 (-2.34, 1.85) 0.8163
centre no. 10 -1.88 (-4.86, 1.10) 0.2169
centre no. 11 -1.76 (-4.96, 1.45) 0.2825
centre no. 12 0.50 (-2.89, 3.90) 0.7702
centre no. 13 -0.50 (-2.46, 1.46) 0.6166
centre no. 14 -1.13 (-4.17, 1.91) 0.4655
centre no. 15 0.78 (-1.58, 3.13) 0.5176
centre no. 16 1.75 (-0.18, 3.69) 0.0751
Sex (Ref.: Females) Males 1.51 (0.42, 2.60) 0.0068
Therapy (ref: Methadone) Buprenorphine -1.35 (-2.73, 0.03) 0.0557
Education (ref: Primary) Middle -2.10 (-3.59, -0.61) 0.0058
Vocational -3.37 (-5.17, -1.56) 0.0003
Secondary or higher -4.23 (-6.03, -2.43) <0.0001
Employment (ref: Employed) Unemployed 0.48 (-0.59, 1.55) 0.3780
Other 0.21 (-1.58, 1.99) 0.8210
Living status (ref: Parents) Partner 4.85 (3.57, 6.13) <0,0001
Alone 2.25 (1.08, 3.53) 0,0002
Friends -1.62 (-4.54, 1.31) 0.2783
Partner (ref: No steady partner) Steady and unmarried -2.75 (-3.85, -1.65) <0,0001
Steady and married -2.23 (-3.87, -0.59) 0.0076
† Coeff.: regression coefficient; ‡ 95% Confidence Interval; * p-value for the significance of the single factor.Page 5 of 11
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ciation of the duration of the drug use with all the serolog-
ical variables: the OR for a one year increase ranged from
1.13 to 1.19 and was always statistically significant. Sub-
ject not employed had a higher risk of having HIV (OR =
1.86, 95%CI: (1.13, 3.05) for the unemployed and OR =
3.52, 95%CI: (1.63, 7.61) for subject which other classifi-
cations). Unemployed had also a higher risk of having
TPHA (OR = 3.73, 95%CI: 1.26, 11.03). Patients with a
steady relationship with a drug user had a higher risk of
HCV than subjects with stable relationships with a non
drug user (OR = 1.97, 95%CI: 1.16, 3.36). Males had
lower rates of TPHA than females (OR = 0.22, 95%CI:
0.07, 0.74).
Discussion
The study shows a reasonable degree of social integration
for subjects, with a substantial percentage in employment,
a large majority living with parents or sexual partners, and
a majority in stable sexual relationships. Although preva-
lence for HCV remains high, the percentage of HIV posi-
tive patients is considerably lower than ten years ago
effectiveness [16]; a relevant percentage of subjects had
been vaccinated for HBV and the prevalence for syphilis is
extremely low, around 1%.
The educational background of the cohort was lower than
the general population in northern Italy. Available litera-
ture enabled us to compare the educational level of the
cohort with the general population which was aged from
15 years and not from 18. The slight difference of three
years does not itself explain the wide difference in the edu-
cational level. Compared to males, a higher percentage of
female patients had a secondary or higher level of educa-
tion. Educational background seems to be a protecting
Percentage of married subjects (and 95%CIs) by age, com-pa ed to the general population in northern Italy (DUs in grey, general popul tion in black)Figure 4
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the lower the duration of drug use.
Employment has been a traditional measure of drug treat-
ment outcome, and maintaining or improving patient lev-
els of employment reflects treatment effectiveness
[17,18]. Although there is always a certain percentage of
patients who, for various psychological, sociological or
physical reasons, are "unemployable", the employment
rate in this group is substantial, with higher unemploy-
ment levels than the general population in the same geo-
graphical area (Figure 2). Seventy-nine percent of this
study sample were employed compared to 50% of per-
sons treated in NHS-DAUs in Italy [19,20]. For the study
cohort no data are available for employment prior to the
study, so no comparison was carried out. Nonetheless, it
is the general opinion of the personnel in treatment cen-
tres that patients have higher levels of employment today
than in the past. This could be the result among other pos-
sible factors of the different approach to substitutive treat-
ment (methadone and buprenorphine) compared to the
past, with higher doses and easier access to it, for example
by supplying one or more weeks of methadone take-home
doses. Maintenance treatment has become easier, without
interruption in cases of positivity after urine samples, and
increasing the dose of methadone in cases of craving.
Therapeutic schedules are customized and detoxification,
if considered appropriate, is carried out in a planned fash-
ion. Clinicians routinely reduce the frequency of centre
visits for patients who improve and prescribe sufficient
quantities of medication to cover the increased time inter-
vals between visits. In Italy the treatment is totally free of
charge for the patients. Whether these elements, which
certainly helped to provide access to, and the implemen-
tation of, treatment, also helped patients to find work is
not certain and could be investigated further.
Heroin users, women in particular, leave their families
earlier than people of the same age in the general popula-
tion. As the age increases, men tend to stay at home more
than the men in the general population of the same age.
This was different for females, for whose only one every
four lives with her parents. In view of the fact that 77% of
female DUs had a stable partner, (versus only the 46% of
males), this could mean females are better able to create
stable relationships, irrespective of being DUs. On the
other hand, for older males, it seems that family of origin
is the principle source of stability and integration. Prob-
lems associated with drug use involve the family; the role
of the family is therefore important in therapy. In this
regard NHS-DAUs frequently involve the families in treat-
ment, with medication administered at home, family sup-
port during detoxification programmes, etc. More than
half of patients (51%) said they had a stable relationship:
of them, the 28% were married.
There were very strong gender differences in terms of part-
ners with a history of addiction; 77% of female heroin
users reported a stable relationship with partners with a
history of addiction, while only 33% of males reported
having partners with histories of addiction. These findings
are similar to other studies [21,22]. There is evidence that
the influence of the partner on drug treatment may differ
among males and females. Some studies have shown that
males are more likely to seek treatment due to pressure
from their families and/or partners [23], while women
receive less support from partners and relatives [24]. Drug
addiction is often more damaging for women than for
men, due to concurrent problems relating to prostitution
and violence in intimate relationships. Lack of emotional
support in relationship with partners and having DUs in
one's social network fosters relapse and lack of compli-
ance with treatment programs [25]. It may be helpful to
provide coordinated treatment to couples where both
have a history of addiction: this could be particularly
important for female DUs.
The high percentage of subjects who were in stable rela-
tionships with partners without histories of heroin addic-
tion, if on one hand is a sign of gradual integration into
social life, on the other hand raises the issue of possible
transmission of blood-borne viruses from the DUs to their
sexual partners [26]. It has been reported that a partner in
a "risk category" is more dangerous than "safe sex" with
many partners who are not in a risk category [27]. Previ-
ous research has shown that condoms are less likely to be
used in stable relationships than in occasional or non-
cohabiting relationships [28]. It has been reported that
28% of males and 70% of females who become HIV pos-
itive have no identifiable risk factor [29]. Recently there
has been a change in the pattern of HIV infection in Italy,
with a gradual decrease of the epidemic among DUs, and
Table 3: Serology of 1091 DUs by gender
No. of subjects (%)
Serology Female* Male* Total* p*
HIV Negative 138 (80.7) 761 (82.7) 899 (82.4) 0.040
Positive 29 (17.0) 107 (11.6) 136 (12.5)
Unknown 4 (2.3) 52 (5.6) 56 (5.1)
HBV Negative 47 (27.5) 195 (21.2) 242 (22.1) 0.096
Positive 76 (44.4) 385 (41.8) 461 (42.2)
Unknown 6 (3.5) 55 (6.0) 61 (6.0)
Vaccinated 42 (24.6) 285 (31.0) 327 (30.0)
HCV Negative 33 (19.3) 209 (22.7) 242 (22.2) 0.806
Positive 127 (74.3) 657 (71.4) 784 (71.9)
Unknown 11 (6.4) 54 (5.9) 65 (6.0)
TPHA Negative 128 (74.9) 679 (73.8) 807 (74.0) 0.060
Positive 6 (3.5) 11 (1.2) 17 (1.5)
Unknown 37 (21.6) 230 (25.0) 267 (24.5)
Percentages by column; *p-value of the chi-square test for association.Page 7 of 11
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[30]. This confirms the importance of including the social
network and partners of DUs in strategies for the preven-
tion of infectious diseases.
Infectious diseases must be considered an important
aspect of the potential social integration of patients. In
fact these diseases can cause very serious illness, penaliz-
ing employment potential and general health if not
treated and followed up. In addition, the diseases can be
transmitted to others, potentially restricting interpersonal
and sexual relations. Twelve percent of the group was pos-
itive for HIV, a substantial reduction from 26% ten years
ago [16]. The percentage is higher for females than males
(17% vs 12%), as in the country and in other countries as
a whole: in Vancouver the percentages are females 35.2%
vs males 25.8% [31], and in Catalonia-Spain 42.1% for
females vs 35.9% for males [3,32]. This could be the con-
sequence of the higher sexual risk of women DUs, as dem-
onstrated by the higher rate of syphilis (Table 4).
Unemployment and higher age were risk factors for HIV,
whilst a rich educational background seems to act as a
protection. In our opinion, the reduction in prevalence,
although partly due to the death of many infected patients
in recent years [10,33], reflects changes in lifestyles and
the implementation of risk reduction policies. Young
DUs, for example, inhale significantly more than older
DUs. HCV seroprevalence is high, more than 70%,
increasing with the time of drug use, making this the most
prevalent infection. Nevertheless, prevalence was lower
among patients under 25 years of age (35%): for this rea-
son among young adult DUs there is enough time
between starting drug use and HCV infection to target
them for prevention [34], even in a population with a very
high prevalence for HCV such as that of the present study.
A moderate percentage of the patients had been exposed
to HBV. Thirty per cent of the cohort were vaccinated
against HBV, the highest percentage for heroin drug users
in Europe, as reported in literature [3,35,36]. HBV vacci-
nation among heroin users proved feasible and effective
when integrated into the regular functioning of drug
abuse treatment programs [37,38]. The level of syphilis
infection was low, as previous reported [39]. In recent
years, a large number of sex workers have arrived in Italy
from other countries [40]. This has led to the gradual
reduction of participation in commercial sex work by Ital-
ian drug users. The percentage of Italian nationals among
sex workers in Italy has fallen from over 80% at the begin-
ning of the 90s to less than 10% currently [41,42]. In
northern Italy, syphilis is associated with commercial sex
work but not with drug use [39]. Unemployment seems to
increase the risk of blood-borne and sexually transmitted
diseases.
Conclusion
The patients in this study show a reasonable level of social
integration. We would suggest that two factors could be
primarily responsible for this level of integration. First,
these subjects receive effective long-term maintenance
treatment for their addiction. Most receive substitutive
treatment in a more flexible and customized manner than
in the past. A harm reduction approach by health opera-
tors places the emphasis on reducing the negative conse-
quences of drug use, with the goal of gradually limiting
these consequences. This contrasts with the rehabilitation
approach that favours abstinence as the primary goal of
drug treatment. Harm reduction advocates acknowledge-
ment that although many DUs may never achieve total
abstinence, they can improve their physical health and
social functioning [43]. Secondly, northern Italy has a low
unemployment rate (4%) and is economically productive
(mean annual per capita GDP: € 20,286). The demand for
labour undoubtedly leads to the hiring of more people in
drug abuse treatment than would occur in areas with
higher unemployment rates. Heroin addiction and other
drug abuse problems clearly can occur in societies with all
varieties of economic conditions, but relative economic
prosperity may increase the likelihood of the social inte-
gration of heroin users who enter treatment.
Several study limitations should be acknowledged. Firstly,
there was no data on the pre-treatment conditions of these
patients. Secondly, the sample contained only patients
who had been in treatment for at least six months,
although the exact duration of treatment was not known.
Thirdly, a number of patients left the programme prema-
turely, often under unfavourable circumstances. Forth,
behaviour data were self-reported and potentially subject
to a social desirability bias. The interviewers were highly
experienced in working with DUs, however, and research
has generally shown that self-reports from DUs are valid
[44]. Finally, the study contains a non-random sample of
patients from a non-random sample of centres.
In most European countries, between 70–75% of the
money spent on the drug problem goes into the criminal
justice system and the remainder into social and health-
care programs. There is substantial room for devoting
more resources for a better treatment of DUs [3]; this,
combined with a favourable economical setting in the
society, may enhance social integration of persons with
history of heroin use.
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Table 4: Association between serological status and social-integration conditions**
Characteristics HIV HBV HCV TPHA
OR 95%CI* OR 95%CI* OR 95%CI* OR 95%CI*
Centre centre no. 1 1 1
centre no. 2 1.71 (0.37,7.99) - - 6.63 (1.26,34.98) - -
centre no. 3 1.85 (0.54, 6.27) - - 2.52 (1.09,5.85) - -
centre no. 4 1.73 (0.49, 6.07) - - 13.23 (2.73,64.17) - -
centre no. 5 1.44 (0.48, 4.33) - - 3.74 (1.54,9.06) - -
centre no. 6 1.74 (0.44, 6.97) - - 6.88 (1.72,27.56) - -
centre no. 7 1.26 (0.25, 6.39) - - - - - -
centre no. 8 0.94 (0.22, 3.99) - - 1.93 (0.67,5.62) - -
centre no. 9 1.53 (0.47, 5.01) - - 2.93 (1.25,6.83) - -
centre no. 10 3.84 (0.89, 16.53) - - 1.13 (0.36,3.62) - -
centre no. 11 - - - - 1.41 (0.44,4.52) - -
centre no. 12 2.91 (0.64, 13.25) - - 11.69 (1.31,104.25) - -
centre no. 13 1.05 (0.33, 3.41) - - 2.06 (0.99, 4.29) - -
centre no. 14 0.65 (0.06, 6.45) - - 2.49 (0.77, 8.08) - -
centre no. 15 0.61 (0.14, 2.64) - - 1.58 (0.65, 3.86) - -
centre no. 16 0.85 (0.27, 2.65) - - 0.77 (0.37, 1.58) - -
Age one year increase 1.01 (0.95, 1.07) 1.01 (0.97, 1.05) 0.99 (0.95, 1.03) 1.00 (0.87, 1.15)
Sex Female 1 1 1 1
Male 0.64 (0.37, 1.11) 1.14 (0.70, 1.87) 0.75 (0.44, 1.29) 0.22 (0.07, 0.74)†
Duration of the drug use one year increase 1.14 (1.08, 1.21)† 1.13 (1.09, 1.18)† 1.19 (1.14,1.24)† 1.14 (1.00, 1.31)†
Education Primary 1 1 1 1
Middle 0.68 (0.35, 1.31) 1.18 (0.66, 2.11) 1.83 (0.92, 3.61) 0.91 (0.18, 4.72)
Vocational 0.42 (0.16, 1.07) 0.95 (0.44, 2.06) 1.24 (0.56, 2.75) 1.17 (0.16, 8.70)
Secondary or higher 0.48 (0.19, 1.20) 0.57 (0.27, 1.22) 1.26 (0.56, 2.83) 0.51 (0.04, 6.44)
Employment Employed 1 1 1 1
Unemployed 1.86 (1.13, 3.05)† 1.62 (0.98, 2.67) 1.62 (0.92, 2.85) 3.73 (1.26,11.03)†
Other 3.52 (1.63, 7.61)† 0.92 (0.37, 2.24) 0.94 (0.56, 1.58) 1.47 (0.16, 8.70)
Living status Parents 1 1 1 1
Partner 1.52 (0.69, 3.38) 1.18 (0.66, 2.11) 0.94 (0.56, 1.58) 0.52 (0.10, 2.61)
Alone 1.05 (0.56, 1.96) 0.88 (0.52, 1.48) 1.67 (0.39, 5.66) - -
Friends 0.58 (0.06, 5.25) 1.59 (0.43, 5.86) 1.48 (0.93, 2.98) 0.86 (0.20, 3.75)
Partner Steady, non D.U. 1 1 1 1
Steady and D.U. 1.80 (0.98, 3.32) 1.28 (0.76, 2.17) 1.97 (1.16,3.36)† 0.23 (0.04, 1.21)
No partner 1.73 (0.79, 3.80) 1.32 (0.77, 2.26) 1.38 (0.86, 2.23) 0.43 (0.10, 1.92)
**: Logistic regression adjusted by recruitment unit, sex, age and duration of drug use; due to sparseness, the adjustment for recruitment site was 
omitted for HBV and TPHA; *: 95% Confidence Interval; †: p-value < 0.05.Page 9 of 11
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